Compare Adaptive Biotechnologies Corp (ADPT) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Phillips 66 — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Phillips 66 trades at $223.92 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 22.2× Adaptive Biotechnologies Corp's market cap, and Phillips 66 pays a 2.26% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PSX | |
|---|---|---|
Market Cap | $4.04B | $89.52B |
Sector | Health | Energy |
52-Week High | $25.45 | $224.36 |
52-Week Low | $12.30 | $120.04 |
Enterprise Value | $4.10B | $105.99B |
Dividend Yield | — | 2.26% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
